Powder: -20°C for 3 years | In solvent: -80°C for 1 year
NMDA receptor antagonist 4 (IIc) 是一个非竞争性、电压依赖的、口服活性的 NMDAR 阻断剂,IC50值为1.93 μM。NMDA receptor antagonist 4 可透过血脑屏障,可用于研究阿兹海默症。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
25 mg | ¥ 10,600 | 6-8周 | ||
50 mg | ¥ 13,800 | 6-8周 | ||
100 mg | ¥ 17,500 | 6-8周 |
产品描述 | NMDA receptor antagonist 4 (IIc) is an uncompetitive, voltage-dependent, orally active NMDAR blocker, with an IC 50 of 1.93 μM. NMDA receptor antagonist 4 shows a positive predicted blood-brain-barrier (BBB) permeability, and can be used in Alzheimer's disease research[1]. |
体外活性 | NMDA receptor antagonist 4 (IIc) exhibits competitive interaction with endogenous blocker Mg 2+, and exhibits dependence on membrane potential in the NMDAR channel [1]. NMDA receptor antagonist 4 shows high metabolic stability in human and mice liver microsomes, and shows hERG safety, without obvious cytotoxicity [1]. Cell Cytotoxicity Assay [1] Cell Line: Neuro2A cells Concentration: 1, 10, and 100 μM Incubation Time: 24 h Result: Did not show cytotoxic at the highest concentration tested (100 μM). |
体内活性 | NMDA receptor antagonist 4 (IIc) (0-10 μM) lowers the motor deficits, and protects against Aβ toxicity-related neuronal dysfunction [1]. NMDA receptor antagonist 4 (5 mg/kg/day; p.o.; 4 weeks) improves cell survival and synaptic function in AD through increasing the activity of cell-survival signaling pathways (Fyn-GluN2B-CREB signaling) and preventing internalization of synaptic NMDARs [1]. Animal Model: C. elegans (N2 wild-type, CL2006, CL2122, CL2355) [1] Dosage: 0, 0.1, 0.5, 1.5, and 10 μM Administration: Result: Reduced defective locomotion in CL2006 nematodes. Significantly reversed the chemotaxis behavior of CL2355 nematodes disrupted by Aβ expression. Animal Model: Six months old female 5XFAD mice [1] Dosage: 5 mg/kg/day Administration: Oral administration, 4 weeks Result: Enhanced working memory function. Rescued the expression of GluN2A and postsynaptic density protein (PSD) 95. Increased Fyn phosphorylated levels and correspondingly elevated GluN2B phosphorylation at Tyr1472. Significantly increased p-CREB protein levels in the nucleus. Reverted calbindin D-28K protein levels. |
分子量 | 231.31 |
分子式 | C15H18FN |
CAS No. | 1607589-56-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
NMDA receptor antagonist 4 1607589-56-9 Inhibitor inhibitor inhibit